Page 37 - 2018_10-Haematologica-web

Normal and pathological erythropoiesis
Proc. 2007;82(8):958-966.
71. Valent P, Horny HP. Minimal diagnostic cri-
teria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions. Eur J Clin Invest. 2009;39 (7):548-553.
72. Valent P. Anemia of the elderly (AOE): does it exist and does it matter in clinical practice? Eur J Clin Invest. 2008;38(10):782-783.
73. Bachman E, Travison TG, Basaria S, et al. Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoi- etin/hemoglobin set point. J Gerontol A Biol Sci Med Sci. 2014;69(6):725-735.
74. Arber DA, Hasserjian RP. Reclassifying myelodysplastic syndromes: what's where in the new WHO and why. Hematology Am Soc Hematol Educ Program. 2015;2015:294- 298.
75. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neo- plasms and acute leukemia. Blood. 2016;127(20):2391-405.
76. Strupp C, Nachtkamp K, Hildebrandt B, et al. New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): characteristics of refined MDS types. Leuk Res. 2017;57:78-84.
77. Fouillard L, Labopin M, Gorin NC, et al; Acute Leukemia Working Party of the EBMT. Hematopoietic stem cell transplanta- tion for de novo erythroleukemia: a study of the European Group for Blood and Marrow Transplantation (EBMT). Blood. 2002; 100(9):3135-3140.
78. Ishiyama K, Yamaguchi T, Eto T, et al. Acute megakaryoblastic leukemia, unlike acute erythroid leukemia, predicts an unfavorable outcome after allogeneic HSCT. Leuk Res. 2016;47:47-53.
79. Almeida AM, Prebet T, Itzykson R, et al. Clinical outcomes of 217 patients with acute erythroleukemia according to treatment type and line: a retrospective multinational study. Int J Mol Sci. 2017;18(4).
80. Schmid H, Schiffl H. Erythropoiesis stimu- lating agents and anaemia of end-stage renal disease. Cardiovasc Hematol Agents Med Chem. 2010;8(3):164-172.
81. Ramanath V, Gupta D, Jain J, Chaudhary K, Nistala R. Anemia and chronic kidney dis- ease: making sense of the recent trials. Rev Recent Clin Trials. 2012;7(3):187-196.
82. Mimura I, Tanaka T, Nangaku M. How the target hemoglobin of renal anemia should be. Nephron. 2015;131(3):202-209.
83. Hellström-Lindberg E, Gulbrandsen N, Lindberg G, et al; Scandinavian MDS Group. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony- stimulating factor: significant effects on quality of life. Br J Haematol. 2003;120 (6):1037-1046.
84. Hellström-Lindberg E, van de Loosdrecht A. Erythropoiesis stimulating agents and other growth factors in low-risk MDS. Best Pract Res Clin Haematol. 2013;26(4):401-410.
85. Ludwig H, Fritz E, Kotzmann H, Höcker P, Gisslinger H, Barnas U. Erythropoietin treat- ment of anemia associated with multiple myeloma. N Engl J Med. 1990;322(24):1693- 1699.
86. San Miguel JF, García-Sanz R. Recombinant human erythropoietin in the anaemia of
multiple myeloma and non-Hodgkin's lym-
phoma. Med Oncol. 1998;15:S29-S34.
87. Agnihotri P, Telfer M, Butt Z, et al. Chronic anemia and fatigue in elderly patients: results of a randomized, double-blind, place- bo-controlled, crossover exploratory study with epoetin alfa. J Am Geriatr Soc.
2007;55(10):1557-1565.
88. Agarwal N, Prchal JT. Erythropoietic agents
and the elderly. Semin Hematol. 2008;45(4):
267-275.
89. Hasselblatt M, Ehrenreich H, Sirén AL. The
brain erythropoietin system and its potential for therapeutic exploitation in brain disease. J Neurosurg Anesthesiol. 2006;18(2):132-138.
90. Westenbrink BD, Voors AA, Ruifrok WP, van Gilst WH, van Veldhuisen DJ. Therapeutic potential of erythropoietin in cardiovascular disease: erythropoiesis and beyond. Curr Heart Fail Rep. 2007;4(3):127-133.
91. Brines M. The therapeutic potential of ery- thropoiesis-stimulating agents for tissue pro- tection: a tale of two receptors. Blood Purif. 2010;29(2):86-92.
92. Wilhelm-Leen ER, Winkelmayer WC. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systemat- ic review and meta-analysis. Am J Kidney Dis. 2015;66(1):69-74.
93. Pérez-Ruixo JJ, Cucala-Ramos M, García- Gonzalo E, Del Val Romero B, Valveny N. Between subjects variability in haemoglobin and dose are not associated with the ery- thropoiesis-stimulating agent used to treat anaemia in dialysis: a meta-analysis. Br J Clin Pharmacol. 2013;75(1):15-25.
94. Park S, Fenaux P, Greenberg P, et al. Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a system- atic review and meta-analysis. Br J Haematol. 2016;174(5):730-747.
95. Pfeffer MA, Burdmann EA, Chen CY, et al; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney dis- ease. N Engl J Med. 2009;361(21):2019-2032.
96. Shirazian S, Grant C, Miller I, Fishbane S. How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The use of iron supplementation to reduce ESA dosing in hemodialysis. Semin Dial. 2013;26(5):534-536.
97. Del Vecchio L, Locatelli F. New treatment approaches in chronic kidney disease-associ- ated anaemia. Expert Opin Biol Ther. 2014;14(5):687-696.
98. Bonomini M, Del Vecchio L, Sirolli V, Locatelli F. New treatment approaches for the anemia of CKD. Am J Kidney Dis. 2016;67(1):133-142.
99. Macdougall IC, Ashenden M. Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel ane- mia medications. Adv Chronic Kidney Dis. 2009;16(2):117-130.
100. Raje N, Vallet S. Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss. Curr Opin Mol Ther. 2010;12(5):586-597
101. Arlet JB, Dussiot M, Moura IC, Hermine O, Courtois G. Novel players in b-thalassemia dyserythropoiesis and new therapeutic strategies. Curr Opin Hematol. 2016;23 (3):181-188.
102. Jelkmann W. The ESA scenario gets com- plex: from biosimilar epoetins to activin traps. Nephrol Dial Transplant. 2015;30(4): 553-559.
103. Liu J, Sun B, Yin H, Liu S. Hepcidin: A prom- ising therapeutic target for iron disorders: a systematic review. Medicine (Baltimore). 2016;95(14):e3150.
104. Sugahara M, Tanaka T, Nangaku M. Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease. Kidney Int. 2017;92(2):306-312.
105. Almeida A, Fenaux P, List AF, Raza A, Platzbecker U, Santini V. Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS). Leuk Res. 2017;52:50-57
106. Arber DA. Revisiting erythroleukemia. Curr Opin Hematol. 2017;24(2):146-151.
107. Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood. 2006;108 (5):1652-1660.
108.Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood. 2010;115(17):3589-357.
109. Marty C, Pecquet C, Nivarthi H, et al. Calreticulin mutants in mice induce an MPL- dependent thrombocytosis with frequent progression to myelofibrosis. Blood. 2016;127(10):1317-1324.
110. Shide K, Kameda T, Yamaji T, et al. Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib. Leukemia. 2017;31(5):1136-1144.
111. Rumi E, Harutyunyan A, Elena C, et al. Identification of genomic aberrations associ- ated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm. Am J Hematol. 2011;86(12):974-979.
112. Cerquozzi S, Tefferi A. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a liter- ature review of incidence and risk factors. Blood Cancer J. 2015;5:e366.
113. Alvarez-Larrán A, Senín A, Fernández- Rodríguez C, et al. Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2017;178(5):764-771.
114. Hidalgo López JE, Carballo-Zarate A, et al. Bone marrow findings in blast phase of polycythemia vera. Ann Hematol. 2018;97 (3):425-434.
115. Grossmann V, Bacher U, Haferlach C, et al. Acute erythroid leukemia (AEL) can be sepa- rated into distinct prognostic subsets based on cytogenetic and molecular genetic charac- teristics. Leukemia. 2013;27(9):1940-1943.
116.Cervera N, Carbuccia N, Garnier S, et al. Molecular characterization of acute ery- throid leukemia (M6-AML) using targeted next-generation sequencing. Leukemia. 2016;30(4):966-970.
117. Ping N, Sun A, Song Y, et al. Exome sequenc- ing identifies highly recurrent somatic GATA2 and CEBPA mutations in acute ery- throid leukemia. Leukemia. 2017;31(1):195- 202.
118. Montalban-Bravo G, Benton CB, Wang SA, et al. More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood. 2017;129(18):2584-2587.
haematologica | 2018; 103(10)
1603